4//SEC Filing
Tessier-Lavigne Marc 4
Accession 0001714899-22-000148
CIK 0001714899other
Filed
Nov 27, 7:00 PM ET
Accepted
Nov 28, 7:30 PM ET
Size
8.0 KB
Accession
0001714899-22-000148
Insider Transaction Report
Form 4
Tessier-Lavigne Marc
Director
Transactions
- Sale
Common Stock
2022-11-23$30.48/sh−20,000$609,600→ 1,870,356 total
Holdings
- 78,848(indirect: By Trust)
Common Stock
- 79,173(indirect: By Trust)
Common Stock
Footnotes (6)
- [F1]The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.15 to $31.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]Includes 5,986 unvested restricted stock units.
- [F4]The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee.
- [F5]The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee.
- [F6]The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee.
Documents
Issuer
Denali Therapeutics Inc.
CIK 0001714899
Entity typeother
Related Parties
1- filerCIK 0001437435
Filing Metadata
- Form type
- 4
- Filed
- Nov 27, 7:00 PM ET
- Accepted
- Nov 28, 7:30 PM ET
- Size
- 8.0 KB